Haynes and Boone’s Pharmaceuticals Industry Group provides experience in pharmaceuticals, biotechnology and biosimilars at the intersection of the pharmaceutical, biotechnology, drug delivery and medical device arts. Our attorneys have vast and varied experience in pharmaceuticals and can meet clients’ intellectual property, regulatory and compliance, and business transaction needs. We represent a wide array of emerging growth, middle stage and Fortune 100 companies in the pharmaceutical industry, and have a knowledge base and skill set that is particularly helpful to our clients in this field. Our practitioners represent clients in technology areas such as:
- Pharmaceutical compounds, compositions, formulations, and methods for the treatment, diagnosis, screening for, and prevention of various cancers, viral and bacterial infections, dementia, substance dependency, and cardiovascular, ocular, neurological, and dermatological diseases, conditions, and symptoms related thereto, including solid and liquid oral formulations, injectables, intranasal sprays, transdermal substrates, and other routes of administration
- Represented a major pharmaceutical company in connection with in-licensing Phase 3 compounds and joint control of testing and approval process.
- Represented a major pharmaceutical company in connection with a long-range joint development and marketing collaboration.
- Represented a major pharmaceutical company in connection with multiple copromotion agreements.
Haynes Boone Partner Vincent Shier was featured in an IP Watchdog article. Below is an excerpt: This morning, Senator Thom Tillis (R-NC) introduced the Vincof 2022, S.4734, which would amend the U.S. Patent Act to clarify the application of 35 U.S.C. Section 101 to certain technologies. While the bill was welcomed by many in the intellectual property (IP) community, since it would abrogate or wea [...]